Letter from the CEO

Global Health Surveillance

Safety & Protection

Paving the Way for Safety

Improving Human Health: Impacts in Cancer

Improving Human Health: Therapeutics For Neurological Disorders & Stroke

Power Forward

Revenue

Board of Directors

Executive Team

Board of Trustees

Contents 3

14

4

16

6

16

9

17

10

18

12

2

That’s how we operate at MRIGlobal. Our clients say what they most value about working with us is the relationship: we are partners who see the project through completion.

World events and our love of science fuel our work.

That work impacts the armed services by keeping them safe; cancer and stroke victims by refining new treatments; sick patients by developing new diagnostic assays; drivers by creating safer road designs; and rural Africans by designing renewable power plans for remote villages.

Making the world a better place matters to the men and women of MRIGlobal.

THE SCIENCE YOU EXPECT.THE PEOPLE YOU KNOW.

FROM THE CEO

MRIGlobal achieved remarkable success in 2018, and the coming year promises to be exciting as we celebrate 75 years of making a difference all over the globe.

To celebrate our 75th anniversary, we invite our friends to join us on September 12 for a special luncheon featuring Bill Nye the Science Guy. There we’ll celebrate our storied past and look forward to our next 75 years of creating solutions using science and technology for a safer, healthier, and more sustainable world.

Thomas M. Sack, Ph.D.President and Chief Executive Officer

With subject matter experts across our diverse scientific areas, MRIGlobal impacts the safety and health of our world.

3

MRIGlobal is a trusted partner known for scientific expertise in the areas of infectious disease, biological and chemical threats, and antimicrobial resistance. We lead scientific thought in research and development; test and evaluation; and laboratory training.

IMPACT: Subject matter experts across our diverse research areas use science and technology to impact the safety, sustainability, and health of the world.

HEALTHSURVEILLANCEGLOBAL

DIAGNOSING, ASSESSING, AND TREATING INFECTIOUS DISEASE AND BIOLOGICAL/CHEMICAL THREATS

4

EXPERTS WITH IMPACTDr. Gene Olinger recently published research on the assumed lifetime immunity of Ebola survivors in The Journal of Infectious Diseases. Researchers tracked down Ebola survivors willing to give blood samples and found that all had antibodies that reacted, some very strongly, to three different Ebola proteins. This implies that Ebola survivors may retain a lifetime immunity to future infections.

HIGH CONFIDENCE, RAPID PATHOGEN DETECTION IN FIELD-FORWARD ENVIRONMENTSPan-Genomics for Infectious Agents (PanGIA) is MRIGlobal’s simple, deployable Sample-to-Sequence methodology. The platform detects human pathogens in clinical and environmental samples. Developed for the Defense Threat Reduction Agency’s Chemical and Biological Technologies Directorate, PanGIA reduces the time from sample-to-answer for pathogen detection, enabling treatment to start sooner.

IMPACT: PanGIA’s rapid and specific pathogen detection with actionable results saves lives. In 2018, PanGIA was the only Defense Threat Reduction Agency project to be honored by Department of Defense (DoD) for the Value Engineering Achievement Award.

ANSWERING AN SOS FOR INTERNATIONAL HEALTH CARE WORKFORCEThousands of Americans and U.S. Military personnel reside in countries affected by outbreaks of highly pathogenic infectious diseases such as Ebola. To provide emergency medical care to those who are there to help mitigate such epidemics, the U.S. Department of State selected MRIGlobal to produce two Portable Biocontainment Care Module (PBCM) units. The PBCM units can accommodate caregivers and up to four patients who may be infected, while providing flexible biocontainment capabilities for temporary isolation and full biocontainment.

IMPACT: PBCM provides U.S. citizens and military aid volunteers infected with a highly pathogenic infectious disease medical care under full biocontainment while being air lifted to facilities with the highest health care standards.

IMPROVING EBOLA VIRAL DISEASE DIAGNOSTIC CAPACITY WORLDWIDEWhen the World Health Organization declared a Public Health Emergency of International Concern in response to the Ebola outbreak in West Africa on August 8, 2014, MRIGlobal was there to help.

Now in our fourth year of engagement with four West African nations, we continue to support Ebola outbreak recovery efforts. MRIGlobal teams work with host-nation governments, national health care personnel, members of the international donor community, and contractor partners to enhance each nation’s capacity to manage future disease outbreaks. We staff diagnostics laboratories; train personnel on biosurveillance-related technical skills, biosafety, and security; and support test and evaluation, supply and logistics, maintenance and operations. Our experts provide guidance during laboratory facility design, construction, and engineering efforts.

IMPACT: In-the-field containment, diagnosis, training and tools prevent the spread of highly infectious diseases that threaten global health.

5

& PROTECTIONSAFETY

DEVELOPMENT OF A HIGHLY PORTABLE DEVICE FOR THE IDENTIFICATION OF INFECTIOUS DISEASE AGENTSThe Joint Product Management Office for Diagnostics (JPMO-DX) has contracted with MRIGlobal to develop and manufacture a portable, hand-held, sample-to-answer system for the diagnosis of infectious diseases and biological warfare agents (BWAs) in symptomatic individuals in austere battlefield environments.

IMPACT: The Department of Defense’s mission is enhanced with this simple-to-use, CLIA-waivable, and FDA-cleared platform that includes integrated, automated sample preparation for whole blood and detection system paired with real-time TaqMan PCR assays for nine high-priority diseases.

IN VITRO DIAGNOSTICS PROPELS PRODUCT DEVELOPMENT FOR PATIENT HEALTHMRIGlobal manages a variety of large commercial in vitro diagnostic programs. These programs range from the development of cutting-edge, molecular-based assays focused on detecting low levels of sexually transmitted diseases to the advancement of novel, highly-sensitive diagnostic panels for identifying and quantifying different strains of the influenza virus.

From multimillion-dollar government programs to working on breakthrough development projects for five of the top ten global in vitro diagnostic companies, MRIGlobal has made a significant contribution within the in vitro diagnostics infectious disease market.

IMPACT: New in vitro diagnostic tools increase the opportunity for reliable diagnoses resulting in more effective treatment.

EXPERTS WITH IMPACTMRIGlobal scientists Dr. Robert Casillas and Dr. Claire Croutch published “Sulfur mustard induced mast cell degranulation in mouse skin is inhibited by a novel anticholinergic bifunctional prodrug” in Toxicology Letters. Their paper represents on-going efforts to develop novel medical countermeasures against chemical and biological agent exposure.

6

DELIVERING SOFTWARE INTEGRATION FOR STRYKER MOUNTED RECONNAISSANCE WORKING GROUPWarfighters rely on the STRYKER armored vehicle for protection while moving in conflict zones. The customized STRYKER vehicle includes advanced chemical, biological, radiological, and nuclear (CBRN) detection capabilities.

MRIGlobal’s team is developing software systems for the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD). The systems will connect individual CBRN sensor data, GPS location, and communication to integrate and upgrade the STRYKER components into a complete threat intelligence and protection system.

IMPACT: Updating and integrating the STRYKER vehicle improves the mobile protection of warfighters facing chemical or biological warfare threats.

WORLD TRAINING FACILITY FOR CHEMICAL DEFENSE MRIGlobal designed, and is now fabricating and installing, training enhancements to the Chemical Defense Training Facility (CDTF) at Fort Leonard Wood, MO.

The CDTF is the only facility of its kind within the U.S. Department of Defense capable of safely containing toxic materials in support of military training operations. When complete, the CDTF will be the global venue of choice for live toxic chemical, biological, radiological, and nuclear defense training.

IMPACT: Upgrades to the CDTF enhance personnel training that is central to the U.S. DoD effort to defend against weapons of mass destruction threats.

7

& PROTECTIONSAFETY

ON THE FRONTLINE

THE FUTURE IS HERE: MERCURY LAB TRAVELS TO THE SAMPLEMRIGlobal’s Mercury Lab is a truly portable molecular biology laboratory that delivers the power of next-generation sequencing technology to the point of need.

Mercury Lab provides all the necessary operational equipment in a human-centered, laboratory-workbench design. The result enables rapid, reproducible deployment of advanced genomic technologies to field-forward locations.

When deployed to Peru, MRIGlobal’s team used Mercury Lab to effectively process alpha virus-infected human serum samples. Mercury Lab was displayed at the International Symposium on Human Identification meeting in Phoenix, AZ, and was highlighted in a seminar at the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service facility in Ames, IA.

Further development focuses on human identification and forensics, infectious disease diagnostics, and food/agriculture safety.

Alpha-prototypes of Mercury Lab are available for field trials with prospective customers, trade show exhibitions, and internal R&D.

IMPACT: Reliable field diagnostics save time and expedite treatment decisions. Mercury Lab travels to the sample, eliminating sample transport, logistical hurdles, and sample analysis delays.

8

ON THE FRONTLINE

WAY FOR SAFETYPAVINGBEYOND RUBBER HITTING THE ROAD

SAFER ROADS FOR UTAH MRIGlobal leads a project to assist Utah’s Department of Transportation and local agencies in safety management and planning.

Using protocols developed by the U.S. Road Assessment Program (usRAP) and its international partner, the International Road Assessment Program (iRAP), MRIGlobal is developing investment plans to increase the safety of Utah’s roads.

TEAM RECEIVES PRESTIGIOUS TRANSPORTATION INDUSTRY AWARDMRIGlobal staff were recognized with the American Association of State Highway and Transportation Officials inaugural Ron C. Pfefer Best Paper Award for their work entitled “Application of Highway Safety Manual Method for Ramp Crash Prediction to Loop and Diamond Ramps.” The authors are Doug Harwood, Dr. Darren Torbic, and Karin Bauer.

STEERING THE FUTURE OF TRANSPORTATIONMRIGlobal is impacting the future of automated and connected vehicles in Kansas City. As a member of both the Mid-America Regional Council’s KINETIC Steering Committee and Regional Automated Vehicle Taskforce, the team is exploring how rapidly changing transportation technologies will impact transportation in the region.

IMPACT: Decades of MRIGlobal’s transportation industry expertise will guide the future for safe road travel.

The unsung heroes of our roadways are the civil and transportation engineers focused on increasing safety by evaluating rapid advances in technology, roadway design, and mobility options.

THE

EXPERTS WITH IMPACTDoug Harwood, P.E., has led innovations in the transportation industry

for 45 years. Three-time recipient of the Transportation Research Board’s D. Grant Mickle Award and four-time honoree of the Chairman’s Award, Harwood is one of the world’s

leading experts in road assessment protocols.

IMPACT: MRIGlobal engineers and analysts study data and develop models to create design guidance in order to ensure the roads we travel are designed and paved with safety in mind.

ROADWAY DESIGN WITH TRUCKS IN MIND Roadway design - lane width, turn lanes, curb returns, and driveways - has often focused on serving passenger cars, but trucks also require safe and efficient travel on roadways. MRIGlobal leads the development of a guidelines document for the National Cooperative Highway Research Program that will assist highway agencies across the country in designing roadways with ample access for trucks and cars.

IMPACT: Designing roadways to accommodate trucks makes travel safer for all vehicles.

9

SINCE 1948, MRIGLOBAL HAS SUPPORTED CANCER RESEARCH Our goal is to develop faster bench-to-bedside processes to deliver therapeutic drugs to clinics for efficacy testing. We bridge the gap between drug discovery and commercialization for large-scale manufacturing. This critical role ensures that drugs continue through the complex investigational new drug application process. The highly regulated work ensures drugs are safe for patients based on rigorous method validation and stability testing.

THERAPEUTICS SHELF LIFE EVALUATION AND DOSAGE FORMULATIONS With the National Cancer Institute (NCI), MRIGlobal supports the development of new medications through shelf life stability testing for the treatment of many cancer types. For more than 15 years, MRIGlobal has partnered with the NCI and was recently awarded a five-year program from the National Institutes of Health National Cancer Institute for Shelf Life Evaluation of Investigational Dosage Forms. The program is from NCI’s Division of Cancer Treatment and Diagnosis and supports the development of novel anti-cancer therapeutic agents.

IMPACT: Our research ensures stored medication maintains its quality and that the dosage is correct. MRIGlobal establishes shelf life stability of the drug such that the storage conditions (under which the drug maintains its potency with no adverse impurities) is well-documented. This ensures that clinical trials around the world are using drugs of consistent high quality.

HUMAN HEALTHIMPROVING

IMPACTS IN CANCER

10

CENTRALIZED CHEMOPREVENTATIVE AGENT REPOSITORY AND DRUG CHEMISTRY SUPPORT PROGRAM MRIGlobal supports The National Cancer Institute (NCI) in developing new medications for the prevention of many types of cancer.

MRIGlobal is in now in its ninth year of operating the Centralized Chemopreventive Agent Repository and Drug Chemistry Support program for the National Institutes of Health (NIH)/NCI/Division of Cancer Prevention. This program serves as a centralized source of agents for use in studies by the Division of Cancer Prevention (DCP) and supports the translation of promising laboratory discoveries into effective interventions for the prevention or reduction of cancer.

MRIGlobal experts acquire, track, store, maintain, test, provide quality control, and distribute these investigational agents to NCI DCP designated preclinical and Phase 0/I/II cancer prevention clinical investigational sites.

IMPACT: MRIGlobal facilitates the progress of research to reduce cancer deaths.

TARGETING CHEMOTHERAPEUTICS DIRECTLY TO TUMORSTargeted delivery of drugs via an antibody is an important advancement in cancer treatment. MRIGlobal performed testing on a drug substance for an antibody-drug conjugate designed to directly attack the tumor while reducing overall toxic and systemic effects of chemotherapeutics.

MRIGlobal scientists performed structural elucidation of impurities in the regulatory starting materials and final drug substance using high resolution quadrupole time-of-flight mass spectrometer (QToF), nuclear magnetic resonance spectroscopy and residual solvent headspace analysis. Our chemists proposed potential synthetic pathways to confirm structures suggested by the QToF data and interpreted by the analytical team.

The drug received Breakthrough Therapy designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) for whom prior therapies for metastatic disease have failed.

The FDA also granted ADC Fast Track designation for patients with TNBC and for patients with small-cell lung cancer or non-small-cell lung cancer.

IMPACT: New targeted chemotherapeutics are available for patients with breast and lung cancer.

11

HUMAN HEALTHIMPROVINGNEW THERAPEUTICS FOR NEUROLOGICAL DISORDERS & STROKE

DRUG MANUFACTURING AND FORMULATION FOR THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) Most nervous system disorders lack effective treatment. Additionally, many of the potential neurotherapeutic drugs identified in basic research do not progress to human testing.

MRIGlobal facilitates the development and manufacturing of drug candidates for ultimate use in clinical trials (through our contract with NINDS) that are specific to the needs of its Drug Manufacturing and Formulation Program (DMFP). MRIGlobal develops and prepares active pharmaceutical ingredients (API), conducts pre-formulation and formulation studies, performs analytical method development and validation, and conducts stability studies.

IMPACT: New therapeutics for use in clinical trials are underway for patients with debilitating neurological disorders.

12

ANALYTICAL CHEMISTRY SUPPORTS TOXICOLOGYFor more than 40 years, MRIGlobal’s analytical chemistry expertise has supported the National Toxicology Program (NTP), an interagency program in the U.S. Department of Health and Human Services.

The NTP evaluates health effects of substances to which the public is exposed daily for which there is little to no toxicological data on these substances. The list of substances includes industrial chemicals, pharmaceuticals, pesticides, flame retardants, ionic liquids, natural products, food additives, and polymers.

MRIGlobal manages a large repository of these 5,000-plus diverse chemicals, providing comprehensive chemical characterization of the repository and shipping chemicals to research collaborators (industry, government, and academic) for alternative animal toxicology studies.

We support NTP’s in vivo toxicology studies through development and validation of methods for dose formulation and biological sample quantitation in complex biological matrices and perform acute toxicokinetic studies.

Why is this important? The toxicological effects on human health of daily exposure to low levels of substances are unknown.

MRIGlobal experts use state-of-the-art instrumentation and our 40-plus years of knowledge in method development, validation, and repository management to advance NTP’s mission.

IMPACT: Toxicology studies are being performed to learn the effects of constant exposure to common substances. This enables NTP to inform the public of exposure safety and advance policy decisions regarding public health.

EXPERTS WITH IMPACTThe NTP team is led by Dr. Kristin Aillon and Dr. Lori Smith, both bioanalytical chemists at MRIGlobal with more than 30 combined years of analytical chemistry expertise.

Dr. Aillon manages the team of 20 staff dedicated to working on more than 50 active projects to advance NTP’s mission. Additionally, Dr. William Smith provides scientific technical expertise in method development and instrumentation to ensure MRIGlobal provides scientific data of the highest quality and accuracy that meet NTP’s expectations.

13

FORWARDPOWER

MINIGRIDS & RENEWABLE TESTING CENTERS

FEASIBILITY STUDY FOR POWERING WEST AFRICA Half a world away in West Africa, MRIGlobal is conducting a comprehensive feasibility study for the electrification of 31 villages in three of the largest regions in rural Senegal using solar-battery diesel hybrid minigrids. Working with Energie Rurale Africaine (ERA) with funding from the U.S. Trade and Development Agency, MRIGlobal’s feasibility and pilot project results will be used to apply for project implementation financing from international banking institutions. MRIGlobal and ERA will eventually scale up the results to build up to 100 minigrids to provide electricity access to an estimated population of 150,000.

IMPACT: Reliable electricity would be life-changing for rural Senegal’s 5.5 million people, 62 percent of whom have no access to electricity. The results from this project could potentially help the 1.1 billion other people around the word without access to electricity.

SOLARTAC & SOLAR GARDENSolar Technology Acceleration Center (SolarTAC) expanded its mission to include a new microgrid test and demonstration facility, GridNXT. This addition facilitates field testing of new microgrid technologies.

SolarTAC also hosts Denver Housing Authority’s Solar Garden, a shared solar array with grid-connected subscribers to provide low-cost energy for approximately 500-700 Denver homes.

Photos by NREL

EXPERTS WITH IMPACTDustin Smith, Executive Director of the Solar Technology Acceleration Center (SolarTAC), was named Colorado Cleantech Industries Association’s 2018 Innovator of the Year.

IMPACT: Solar energy is moving to the next level. At SolarTAC and GridNXT, technology companies can test their individual components under realistic environmental conditions. Subscribers to the Solar Garden are expected to realize a 30 percent reduction in their energy bills.

14

ALLIANCE FOR SUSTAINABLE ENERGY: M&O OF NRELMRIGlobal is a partner in the Alliance for Sustainable Energy, the management and operating contractor for the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL).

NREL’s science and technology accomplishments abound in grid modernization and fuel cell, bioenergy, and solar energy technologies. Fuel Cell Technologies achieved a two-fold improvement in fuel cell catalyst performance and demonstrated alkaline membrane durability of 600 hours. Researchers validated renewable energy scenarios with large-scale electrolyzers to produce hydrogen, showing that power fluctuations could be reduced by up to 65 percent.

Catalytic Fast Pyrolysis and upgrading projects exceeded the highly ambitious Bioenergy Technologies Office research goal of showing an overall carbon conversion efficiency of 36 percent from biomass to fuel, by attaining a carbon efficiency of 40 percent, in order to enhance economics for the technology pathway.

In solar, NREL improved Dynamic Hydride Vapor Phase Epitaxy for processing gallium-arsenide solar cells and achieved a sunlight conversion efficiency of 25.3 percent with deposition rates as high as 3 micrometers per minute. Further, the team demonstrated that by engineering critical interfaces, perovskite solar cells retained 94 percent of their starting efficiency after 1,000 hours of stress testing.

IMPACT: NREL’s innovations improve the way we generate, consume, store, and distribute renewable energy.

NREL INNOVATIONS NREL received two R&D 100 Awards from Research & Development (R&D) Magazine in 2018. The two NREL awards are for foreseeTM Energy Management System and Nitrilation to Acrylonitrile Process.

The foreseeTM Energy Management System relies on user preferences to control and coordinate a home’s connected appliances and electronics. The software first asks users to rank what is most important to them about living in their home. Then, it takes those preferences into account and automatically adjusts the devices accordingly.

NITRILATION TO ACRYLONITRILE PROCESSIn plotting a course for the future, NREL researchers followed a road map from 1916. Their guide — a journal article penned by two chemistry professors from Johns Hopkins University — illuminated a path toward a groundbreaking new method to make the key carbon fiber precursor acrylonitrile (ACN) from renewable sources.

Ongoing research by chemical engineer Eric Karp and others at NREL could lead to a cleaner method of transforming ACN into carbon fiber, replacing petrochemicals with biomass as the starting point.

Taking a page from history, Karp and his colleagues successfully produced 50 grams of bio-derived ACN. That capped the first phase of a DOE-funded program. The second phase, now underway, calls for the production of 50 kilograms of ACN that will be converted into carbon fiber and tested.

“Carbon fiber is this amazing lightweight material,” Karp said. “Imagine replacing all of the steel and aluminum in a car with carbon fiber. Think of how far a car would go with the gas mileage you could get. You’re looking at 60 miles per gallon for the average car on the road with existing engine technology.”

15

2018 COMBINED REVENUE

Chairman Vice Chairman

BOARD OF DIRECTORS

David F. Oliver Attorney

BerkowitzOliver LLP

Malcom M. Aslin Retired Chairman & Chief Executive Officer

Aslin Group, Inc.

Research OperationsNREL

Combined

387395

379

485467 471

9088 84

384

76

412

109460

521

FY2017 FY2018FY2015 FY2016FY2014

Revenue ($M)

Pamela R. BernekingCommunityAmerica Credit Union

David B. Dillon, J.D.Retired CEO The Kroger Company

Alexander G. Garza, M.D., M.P.H.SSM Health

Douglas A. Girod, M.D. University of Kansas

Leo E. Morton DeBruce Companies

Scott M. Smith, P.E.Retired CEO The HNTB Cos.

Board Members

Thomas M. Sack, Ph.D.MRIGlobal

Jefferson W. Tester, Ph.D.Cornell University

16

(L to R) Roger K. Harris, Ph.D., Vice President Sales and Marketing; Thomas M. Sack, Ph.D., President and Chief Executive Officer; Richard T. Fleener, Executive Vice President, Chief Financial Officer and Treasurer; Reachel A. Beichley, J.D., Vice President, General Counsel and Corporate Secretary; Robert A. Conklin, Vice President Research Operations

EXECUTIVETEAM

17

LIFE TRUSTEES

Charles W. BatteySprint Corporation (Retired)

Henry W. BlochH&R Block, Inc.

Richard C. Green, Jr.Corridor InfraTrust Management, LLC

Donald J. HallHallmark Cards, Inc.

William A. HallThe Hall Family Foundation

Irvine O. Hockaday, Jr.Hallmark Cards, Inc. (Retired)

A. Drue Jennings, J.D.Kansas City Power & Light (Retired)

Robert A. KippHallmark Cards, Inc. (Retired)

Louis W. SmithLeawood, KS

Morton I. SoslandSosland Companies, Inc.

TRUSTEES

Dan E. Arvizu, Ph.D. New Mexico State University

Malcom M. AslinAslin Group, Inc. (Retired)

Barbara F. Atkinson, M.D.University of Nevada, Las Vegas

Alan L. AtterburyMidland Properties, Inc.

Guy H. Bailey, Ph.D.University of Texas Rio Grande Valley

Kevin G. BarthCommerce Bank

W. H. Bates, J.D.Lathrop & Gage LLP

Jonathan E. BaumGeorge K. Baum Capital Advisors

William S. BerkleyTension Corporation

Pamela R. BernekingCommunityAmerica Credit Union

Thomas M. BlochKansas City, MO

Daniel P. Bolen, J.D., L.L.M.Bank of Prairie Village

Tom BowserBlue Cross and Blue Shield of Kansas City (Retired)

David R. Bradley, Jr.News-Press & Gazette Company

Barrett BradyHighwoods Properties Inc. (Retired)

Michael BraudeKansas City Board of Trade (Retired)

Arthur D. Brookfield IIFairway, KS

Phillip J. BrownBud Brown Volkswagen, LLC

J. Grant BurchamMOBANK (Retired)

Wayne O. Carter, D.V.M., Ph.D., D.A.C.V.I.M.

Alexander Cartwright, Ph.D.The University of Missouri, Columbia

Michael J. ChesserGreat Plains Energy Inc. and Kansas CityPower & Light (Retired)

Mun Choi, Ph.D.The University of Missouri System

Cecil W. Cupp III, M.D.CUPP Investment Company, LLLP

Thomas B. Curran, S.J.Rockhurst University

Brady J. Deaton, Ph.D.University of Missouri

Peter James deSilva TD Ameritrade

David B. Dillon The Kroger Company (Retired)

Terrence P. Dunn D.D. Ranch Leawood

John M. Edgar, J.D.Edgar Law Firm LLC

Steven L. Edwards Black & Veatch Corporation

Debra Ellies, Ph.D.OsteoGeneX/OSSIFI

E. Frank Ellis P L Strategies, LLC

Melinda Estes, M.D., M.B.A.Saint Luke’s Health System

David W. Frantze, J.D.Stinson Leonard Street, LLP

Alexander G. Garza, M.D., M.P.H.SSM Health

Esther L. George Federal Reserve Bank of Kansas City

Douglas A. Girod, M.D.University of Kansas

Kent Glasscock KSU Institute for Commercialization

Stephen E. Gound Labconco Corporation

Greg M. Graves, P.E.Burns & McDonnellEngineering Company, Inc. (Retired)

Robert K. Green, J.D.Husch Blackwell LLP

Wendy Guillies Ewing Kauffman Foundation

John E. Haaland, Ph.D.MAP/PATH, LLC

Marc B. Hahn, D.O. Kansas City University of Medicine & Biosciences

David E. Hall Hallmark Cards, Inc.

Donald J. Hall, Jr.Hallmark Cards, Inc.

G. Richard Hastings The Netzer Foundation & Saint Luke’s Health System (Retired)

BOARD OF TRUSTEES

18

B. Spencer Heddens IIIBank of America, Kansas City Market (Retired)

James A. HeeterGreater Kansas City Chamber of Commerce(Retired)

Doranne M. HudsonUniversity of Missouri- Kansas City

Jerry P. Jaax, D.V.M.Kansas State University

Edward Randolph Jayne IIHeidrick & Struggles, Inc.

Roy Jensen, M.D.The University of Kansas Cancer Center

Mark R. JorgensonU.S. Bank

Gordon E. Lansford III, CPAJE Dunn Construction Company

Peter S. LeviPolsinelli P.C.

R. Bowen Loftin, Ph.D.University of Missouri

Fred J. Logan, Jr.Logan Logan & Watson, L.C.

Fred W. Lyons, Jr.Hoechst Marion Roussel Inc. (Retired)

Alan R. MarshUBS Financial Services, Inc. (Retired)

Mary V. McClureMcClure Management Consulting, LLC

John N. McConnellLabconco Corporation (Retired)

Patrick J. McCownMcCownGordon Construction (Retired)

John C. McKelveyMRIGlobal (Retired)

Laura Wells McKnightEmbolden

Maria E. MeyersUniversity of Missouri- Kansas City

Michael F. MorrisseyErnst & Young LLP (Retired)

Leo E. MortonDeBruce Companies

General Richard B. MyersKansas State University

Don NissankaExergonix Inc.

Randall L. O’Donnell, Ph.D.Children’s Mercy Hospitals & Clinics (Retired)

Thomas D. O’Grady, P.E.HNTB Corporation

David F. OliverBerkowitzOliver LLP

Timothy T. PettyU.S. Bank

Joseph Reardon, J.D.Greater Kansas City Chamber of Commerce

Robert D. RegnierBank of Blue Valley

Robert J. Reintjes, Sr.Geo. P. Reintjes Co., Inc.(Retired)

David A. RismillerFirsTier Financial, Inc. & America First Financial Institutions Management

Kristy A. SchlossSchloss Engineered Equipment, Inc.(Retired)

Jewel D. ScottCivic Council of Greater Kansas City(Retired)

James C. ShayHallmark Cards, Inc.

Charles W. ShieldsTruman Medical Centers

Robert D. Simari, M.D.The University of KansasMedical Center

Dolph C. Simons, Jr.The World Company

Ronald Slepitza, Ph.D.Avila University

Scott M. Smith, P.E.The HNTB Cos. (Retired)

James L. Spigarelli, Ph.D.MRIGlobal (Retired)

Jimmie T. Stark, CPAPWC (Retired)

Kent W. SunderlandSunderland Foundation

Robert J. Swain Tulsa, Oklahoma

Jefferson W. Tester, Ph.D.Cornell University

Mark C. Thompson, J.D.CCB Financial Corporation

Willis H. Thompson, Jr.Bank One, Oklahoma (Retired)

Vince WagnerAce Wagner Coaching & Consulting

David A. WarmMid-America Regional Council

Maurice WatsonHusch Blackwell

Scott Weir, Ph.D., PharmDKU Medical Center

W. Russell Welsh, J.D.Polsinelli

Deborah L. WilkersonGreater Kansas City Community Foundation

Danette WilsonBlueCross and Blue Shield of Kansas City

Walter H. Wulf, Jr.Monarch Cement Company

REMEMBRANCE 2018

Leonard M. Perlmutter

19

www.mriglobal.org 816-753-7600

Bill Nye The Science Guy Great Minds in Science: The Impacts on our Everyday Lives

SPECIAL GUEST SPEAKER

CELEBRATE MRIGLOBAL September 12, 2019 Sheraton Hotel Crown Center2345 McGee Street, Kansas City, MO 64108 12:00 p.m. - 1:30 p.m. Lunch and Program

Featuring Bill Nye The Science Guy, this event celebrates those who have supported MRIGlobal’s mission over the past 75 years. Join us for an engaging gathering of science enthusiasts, partners, clients, peers, and community.

For more tickets or table sponsorship, please visit www.mriglobalevents.com